PMB-CT01, a BAFF-R targeting CAR-T cell therapy, achieved a 100% complete response rate in relapsed/refractory follicular lymphoma patients. The phase 1 PMB-102 study focuses on safety, optimal dosing ...
The antibiotic polymyxin can pierce the armor of active bacteria, but are ineffective when armor production is shut off in dormant bacteria.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback